Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and … – Nasdaq
|
Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and …
Nasdaq AST-VAC2 is an innovative immunotherapy product that contains mature dendritic cells derived from pluripotent stem cells. These non-patient specific (allogeneic) AST-VAC2 cells are engineered to express a modified form of telomerase, a protein widely … |
